Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system

被引:42
作者
Vanlandingham, Dana L.
Keil, Shawn D. [1 ]
Horne, Kate McElroy
Pyles, Richard
Goodrich, Raymond P.
Higgs, Stephen
机构
[1] CaridianBCT Biotechnol, Lakewood, CO 80215 USA
关键词
APHERESIS PLATELETS; RIBOFLAVIN; LIGHT; TRANSFUSION; EPIDEMIC; RISK;
D O I
10.1111/j.1537-2995.2012.03717.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Chikungunya virus (CHIKV) is a reemerging mosquito-borne virus that has been responsible for a number of large-scale epidemics as well as imported cases covering a wide geographical range. As a blood-borne virus capable of mounting a high-titer viremia in infected humans, CHIKV was included on a list of risk agents for transfusion and organ transplant by the AABB Transfusion-Transmitted Diseases Committee. Therefore, we evaluated the ability of the Mirasol pathogen reduction technology (PRT) system (CaridianBCT Biotechnologies) to inactivate live virus in contaminated plasma and platelet (PLT) samples. STUDY DESIGN AND METHODS: Plasma, PLTs, and phosphate-buffered saline controls were spiked with CHIKV and treated with riboflavin and varying doses of ultraviolet (UV) light using the Mirasol PRT system. Samples were tested before and after treatment for cytotoxicity, interference, and virus titer by titration and quantitative real-time reverse transcriptionpolymerase chain reaction. RESULTS: A significant reduction in CHIKV titer of greater than 99% was recorded after treatment of plasma or PLTs with the Mirasol PRT system, and the titer reduction was directly proportional to the UV dose delivered to the samples. No cytotoxicity of interference was observed in any sample at any treatment dose. CONCLUSION: These data indicate that the Mirasol PRT system efficiently inactivated live CHIKV in plasma and PLTs and could therefore potentially be used to prevent CHIKV transmission through the blood supply.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [41] Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light
    Cardo, LJ
    Rentas, FJ
    Ketchum, L
    Salata, J
    Harman, R
    Melvin, W
    Weina, PJ
    Mendez, J
    Reddy, H
    Goodrich, R
    VOX SANGUINIS, 2006, 90 (02) : 85 - 91
  • [42] Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions
    Drawz, Sarah M.
    Marschner, Susanne
    Yanez, Martha
    Garcia de Coca, Alfonso
    Feys, Hendrik B.
    Deeren, Dries
    Coene, Jose
    TRANSFUSION, 2015, 55 (07) : 1745 - 1751
  • [43] Pathogen inactivation in fresh frozen plasma using riboflavin and ultraviolet light: effects on plasma proteins and coagulation factor VIII
    Stanojkovic, Zoran
    Antic, Ana
    VOJNOSANITETSKI PREGLED, 2011, 68 (01) : 51 - 56
  • [44] Update on pathogen inactivation treatment of plasma, with the INTERCEPT Blood System: Current position on methodological, clinical and regulatory aspects
    Irsch, Johannes
    Seghatchian, Jerard
    TRANSFUSION AND APHERESIS SCIENCE, 2015, 52 (02) : 240 - 244
  • [45] Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products
    Li, J
    de Korte, D
    Woolum, MD
    Ruane, PH
    Keil, SD
    Lockerbie, O
    McLean, R
    Goodrich, RP
    VOX SANGUINIS, 2004, 87 (02) : 82 - 90
  • [46] The effectiveness of riboflavin photochemical-mediated virus inactivation and changes in protein retention in fresh-frozen plasma treated using a flow-based treatment device
    Zhu, Liguo
    Pan, Jichun
    Wei, Chao
    Wang, Haibao
    Xiang, Rong
    Zhang, Jingang
    Wang, Deqing
    TRANSFUSION, 2015, 55 (01) : 100 - 107
  • [47] Preparation and Pathogen Inactivation of Double Dose Buffy Coat Platelet Products using the INTERCEPT Blood System
    Abedi, Mohammad R.
    Doverud, Ann-Charlotte
    JOVE-JOURNAL OF VISUALIZED EXPERIMENTS, 2012, (70):
  • [48] Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies
    Santa Maria, Felicia
    Huang, Yan-Jang S.
    Vanlandingham, Dana L.
    Bringmann, Peter
    PATHOGENS, 2022, 11 (05):
  • [49] Inactivation of severe acute respiratory syndrome coronavirus 2 in plasma and platelet products using a riboflavin and ultraviolet light-based photochemical treatment
    Keil, Shawn D.
    Ragan, Izabela
    Yonemura, Susan
    Hartson, Lindsay
    Dart, Nicole K.
    Bowen, Richard
    VOX SANGUINIS, 2020, 115 (06) : 495 - 501
  • [50] In vitro comparison of platelet storage in plasma and in four platelet additive solutions, and the effect of pathogen reduction: a proposal for an in vitro rating system
    van der Meer, P. F.
    Kerkhoffs, J.-L.
    Curvers, J.
    Scharenberg, J.
    de Korte, D.
    Brand, A.
    de Wildt-Eggen, J.
    VOX SANGUINIS, 2010, 98 (04) : 517 - 524